Two days after it issued its April 25 report on CME, the United States Senate Committee on Finance followed up with a letter to the Accreditation Council for CME, highlighting its concerns that the ACCME’s oversight is insufficient to guarantee that programs are independent of drug company influence.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments
